Proxy Votes Now

Home › Activist investors › Harbert Discovery

Harbert Discovery

Campaign activist. Positions and campaigns from Harbert Discovery’s SEC filings. Updated November 20, 2026.

1current positions
0new or changed in 90 days
0active campaigns
2campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (1)

CompanyStakeSourceFirst disclosedLast changeSince previous filingFlagsStated intent
Enzo Biochem Inc 9.9%5,175,913 shares Schedule 13D/A, filed Jun 25, 2025 Jun 25, 2025 — — — Seeks changes or engagement

Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.

Stated intent (13D Item 4)

Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.

Enzo Biochem Inc · Seeks changes or engagement

“On June 23, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Bethpage Parent, Inc., a Delaware corporation ("Bethpage"), and Bethpage Merger Sub, Inc., a New York corporation and a wholly owned subsidiary of Bethpage ("Merger Sub"). Pursuant to the terms of the Merger Agreement, Bethpage will acquire the Issuer in an all-equity…”

Item 4 in the Schedule 13D/A filed Jun 25, 2025.

Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.

Past campaigns (2)
CompanyOutcome or last statusDateFirst filingHighest stageFilingsMeeting / votes
Transact Technologies Inc Stake reported below 5% Sep 24, 2025 Mar 31, 2022 — latest (2) —
Enzo Biochem IncBoard seats No campaign filings in the last 12 months Feb 20, 2020 Sep 17, 2019 Proxy contest filed latest (22) —
Past positions (2)
CompanyLast stakeSourceOutcomeDate
Transact Technologies Inc 4.3% Schedule 13D/A, filed Sep 24, 2025 Reported below 5% in a 13D/A Sep 24, 2025
Streamline Health Solutions Inc. 0.0% Schedule 13D/A, filed Aug 14, 2025 Exited Aug 14, 2025

How large managers voted in Harbert Discovery’s proxy contests (meetings since July 2023)

Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.

No proxy contest has gone to a vote since July 1, 2023.

Track record

How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.

1Settlement
1No outcome in the filings read
Outcome of each campaign (2)
CompanyOutcomeDetailDateFirst filing
Transact Technologies Inc Settlement agreement with the company Mar 31, 2022 Mar 31, 2022
Enzo Biochem Inc No outcome in the filings read — Feb 20, 2020 Sep 17, 2019

Share price after the first 13D

The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 3 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).

Other disclosed holders around the same time

Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Harbert Discovery’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.

Enzo Biochem Inc · Harbert Discovery first disclosed Jun 25, 2025 · 2 other filings
HolderFormDateStake
Radoff Schedule 13D Jun 25, 2025 0.0%
Battery Ventures XIV, L.P. Schedule 13D Jun 30, 2025 21.8%

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.